Clinical trials: nAMD
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients
Primary objective: To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients.
- Trial name
- NCT07728981
- Testing
- Aflibercept 8mg
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Eye Hospital
Neovascular Age-related Macular Degeneration
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD)…
- Trial name
- NCT06124677
- Testing
- Faricimab
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Age-Related Macular Degeneration
A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)
A 2 parts Phase II study to investigate the effect on central macular thickness of treatment with MG-O-1002 eye drops in participants aged over 45 with neovascular age-related macular degeneration (nAMD)
- Trial name
- NCT05390840
- Testing
- MG-O-1002
- Where
- 6 sites in Thailand
- Volunteers
- 36 people
- Sponsor
- Theratocular Biotek Co.
Neovascular Age-related Macular Degeneration (nAMD)
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
- Trial name
- NCT05161806
- Testing
- SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sandoz
Neovascular Age-Related Macular Degeneration
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
A retrospective, observational, single-arm, non-randomized cohort study of ocular treatment in nAMD patients in Japan who had records of at least 12 months of follow-up after their first brolucizumab intravitreal injection.
- Trial name
- PHEASANT (NCT06699914)
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of…
- Trial name
- NCT05803785
- Testing
- BBC1501
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Benobio Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
- Trial name
- NCT06116890
- Testing
- KHK4951, Aflibercept Injection
- Where
- 84 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neovascular Age-related Macular Degeneration
A Study of IBI302 in Patients With nAMD
This is a multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT04820452
- Testing
- Low dose IBI302, High dose IBI302, Aflibercept
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
- Trial name
- NCT07516132
- Testing
- OTX-TKI
- Where
- 8 sites in United States
- Volunteers
- 850 people
- Sponsor
- Ocular Therapeutix, Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration (nAMD)
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients…
- Trial name
- NCT06487039
- Testing
- EB-203
- Where
- 5 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- EyebioKorea, Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration(nAMD)
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage…
- Trial name
- NCT07088445
- Testing
- Faricimab
- Volunteers
- 35 people
- Sponsor
- Hui Peng
Neovascular Age-Related Macular Degeneration (nAMD)
To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This study aims to preliminarily evaluate the efficacy and safety of GB10 intravitreal (IVT) injection for the treatment of patients with neovascular age-related macular degeneration (nAMD).
- Trial name
- NCT07406438
- Testing
- GB10
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration
Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment.
- Trial name
- DANA (NCT03909425)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Neovascular Age-related Macular Degeneration (nAMD)
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
- Trial name
- NOVA-1 (NCT05769153)
- Testing
- AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant
- Where
- 42 sites in United States
- Volunteers
- 139 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied.
- Trial name
- NCT06929143
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate the efficacy and safety of Aflibercept (produced by CinnaGen Co, Iran) compared with Eylea® (Regeneron, USA) in subjects with Neovascular Age-related Macular Degeneration (nAMD).
- Trial name
- NCT05587062
- Testing
- Aflibercept (CinnaGen Co, Iran), Aflibercept (Regeneron, USA)
- Where
- Iran
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Cinnagen